Travere Therapeutics, Inc.

This biopharmaceutical company identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its commercial product portfolio includes sparsentan, marketed as FILSPARI, an oral medication approved to reduce the decline of kidney function in adults with primary Immunoglobulin A nephropathy. The company also markets tiopronin tablets, under the brand names Thiola and Thiola EC, to treat cystinuria, a rare genetic disorder that causes recurring kidney stones. Additionally, the company advances clinical-stage candidates such as sparsentan for focal segmental glomerulosclerosis and pegtibatinase for classical homocystinuria. It provides these treatments to patient populations with severe, unmet medical needs.

The company is headquartered in San Diego, California. Beyond its domestic operations, its approved therapies have gained regulatory marketing authorization across member states of the European Union, Iceland, Liechtenstein, Norway, and the United Kingdom, alongside commercial distribution launched in Germany and Austria. The firm also relies on regional partnerships to develop and commercialize treatments across international markets including Japan, South Korea, and Taiwan.

Summary of the business section of Travere Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of January 31, 2026, we had 497 full-time employees, with most of those based in the United States and a small number outside of the United States.”